24
Participants
Start Date
December 31, 2004
Primary Completion Date
November 30, 2007
Study Completion Date
June 30, 2008
bortezomib
Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
topotecan hydrochloride
Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
flow cytometry
No description
immunoenzyme technique
No description
immunohistochemistry staining method
No description
laboratory biomarker analysis
No description
University of California Davis Cancer Center, Sacramento
National Cancer Institute (NCI)
NIH
University of California, Davis
OTHER